Morningstar

Nuvation Bio Inc Ordinary Shares - Class A NUVB

Stock XNYS Rating as of Oct 2, 2026

News

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

PR Newswire Sep 17, 2026, 11:30:00 AM
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

PR Newswire Sep 15, 2026, 12:00:00 PM
Nuvation Bio to Participate in Upcoming Investor Conferences

PR Newswire Sep 2, 2026, 8:05:00 PM
Nuvation Bio Granted FDA Fast-Track Designation for Glioma Treatment

Global News Select Aug 20, 2026, 12:53:00 PM
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

PR Newswire Aug 20, 2026, 12:00:00 PM
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

PR Newswire Aug 6, 2026, 11:30:00 AM
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

PR Newswire Aug 4, 2026, 12:00:00 PM
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

PR Newswire Jul 22, 2026, 8:05:00 PM
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

PR Newswire Jul 20, 2026, 12:00:00 PM
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

PR Newswire Jul 6, 2026, 9:09:00 PM
Nuvation Bio Shares Sink Premarket With Plans for Convertible Notes Offering

Global News Select Jun 25, 2026, 12:06:00 PM
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment

Global News Select May 13, 2026, 9:52:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.